ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) plus olaratumab versus dox plus PBO in patients (pts) with advanced soft tissue sarcomas (STS) Journal Article


Authors: Tap, W. D.; Wagner, A. J.; Papai, Z.; Ganjoo, K. N.; Yen, C. C.; Schoffski, P.; Razak, A. R. A.; Broto, J. M.; Spira, A. I.; Kawai, A.; Krarup-Hansen, A.; Le Cesne, A.; Van Tine, B.; Naito, Y.; Park, S. H.; Soldatenkova, V.; Mo, G.; Shahir, A.; Wright, J.; Jones, R. L.
Article Title: ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) plus olaratumab versus dox plus PBO in patients (pts) with advanced soft tissue sarcomas (STS)
Journal Title: Journal of Clinical Oncology
Volume: 37
Issue: 18
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2019-06-01
Language: English
ACCESSION: WOS:000489109800008
DOI: 10.1200/JCO.2019.37.18_suppl.LBA3
PROVIDER: wos
Notes: Meeting Abstract -- Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2019 -- Chicago, IL -- S -- Source: Wos
Altmetric Score